Gilbert PB - Search Results

1

Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials.

Mehrotra DV, Janes HE, Fleming TR, Annunziato PW, Neuzil KM, Carpp LN, Benkeser D, Brown ER, Carone M, Cho I, Donnell D, Fay MP, Fong Y, Han S, Hirsch I, Huang Y, Huang Y, Hyrien O, Juraska M, Luedtke A, Nason M, Vandebosch A, Zhou H, Cohen MS, Corey L, Hartzel J, Follmann D, Gilbert PB. Mehrotra DV, et al. Among authors: gilbert pb. Ann Intern Med. 2021 Feb;174(2):221-228. doi: 10.7326/M20-6169. Epub 2020 Oct 22. Ann Intern Med. 2021. PMID: 33090877 Free PMC article.

2

What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials.

Gilbert PB, DeGruttola VG, Hudgens MG, Self SG, Hammer SM, Corey L. Gilbert PB, et al. J Infect Dis. 2003 Jul 15;188(2):179-93. doi: 10.1086/376449. Epub 2003 Jul 1. J Infect Dis. 2003. PMID: 12854072

3

Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials.

Gilbert PB, Bosch RJ, Hudgens MG. Gilbert PB, et al. Biometrics. 2003 Sep;59(3):531-41. doi: 10.1111/1541-0420.00063. Biometrics. 2003. PMID: 14601754

4

Endpoints in vaccine trials.

Hudgens MG, Gilbert PB, Self SG. Hudgens MG, et al. Among authors: gilbert pb. Stat Methods Med Res. 2004 Apr;13(2):89-114. doi: 10.1191/0962280204sm356ra. Stat Methods Med Res. 2004. PMID: 15068256

5

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.

Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, Sinangil F, Burke D, Berman PW. Gilbert PB, et al. J Infect Dis. 2005 Mar 1;191(5):666-77. doi: 10.1086/428405. Epub 2005 Jan 27. J Infect Dis. 2005. PMID: 15688279 Clinical Trial.

6

Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation.

Li F, Malhotra U, Gilbert PB, Hawkins NR, Duerr AC, McElrath JM, Corey L, Self SG. Li F, et al. Among authors: gilbert pb. Vaccine. 2006 Nov 17;24(47-48):6893-904. doi: 10.1016/j.vaccine.2006.06.009. Epub 2006 Jun 27. Vaccine. 2006. PMID: 16890329

7

A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof-of-concept HIV vaccine trial.

Mehrotra DV, Li X, Gilbert PB. Mehrotra DV, et al. Among authors: gilbert pb. Biometrics. 2006 Sep;62(3):893-900. doi: 10.1111/j.1541-0420.2005.00516.x. Biometrics. 2006. PMID: 16984333

8

A framework for assessing immunological correlates of protection in vaccine trials.

Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG. Qin L, et al. Among authors: gilbert pb. J Infect Dis. 2007 Nov 1;196(9):1304-12. doi: 10.1086/522428. Epub 2007 Oct 2. J Infect Dis. 2007. PMID: 17922394

9

Evaluating a surrogate endpoint at three levels, with application to vaccine development.

Gilbert PB, Qin L, Self SG. Gilbert PB, et al. Stat Med. 2008 Oct 15;27(23):4758-78. doi: 10.1002/sim.3122. Stat Med. 2008. PMID: 17979212 Free PMC article.

10

Evaluating candidate principal surrogate endpoints.

Gilbert PB, Hudgens MG. Gilbert PB, et al. Biometrics. 2008 Dec;64(4):1146-54. doi: 10.1111/j.1541-0420.2008.01014.x. Epub 2008 Mar 24. Biometrics. 2008. PMID: 18363776 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

333 results

Search Page